Please login to the form below
naloxone
This page shows the latest naloxone news and features for those working in and with pharma, biotech and healthcare.
Q&A: Kate Paxton
I was very honoured to develop and launch the esteemed patient advocacy group Families Fighting Flu, and helping to launch the first community-ready nasal naloxone in the US during the
Latest news
-
Insys gets bankruptcy court okay for Subsys sale
a naloxone nasal spray formulation and a sublingual spray formulation of buprenorphine in development.
-
Indivior push to diversify boosted by schizophrenia drug approval
In a press release, the company says its launch – originally slated for the fourth quarter – will now be reviewed in light of a recent court decision relating to Suboxone (buprenorphine/naloxone)
-
FDA panel backs Indivior’s drug to fight opioid addiction
naloxone), another treatment for opioid dependence, and which raised the threat of low-cost copies reaching the market earlier than expected.
-
CHMP backs maintenance therapy for Tesaro's Zejula
Also given the nod were two drugs from Mundipharma intended to help people with opioid addiction – Nyxoid (naloxone) and Zubsolv (buprenorphine/naloxone), while Spanish drugmaker Grifols got the go-ahead for
-
Indivior slumps as patent dispute rises US generic spectre
The UK-listed company - which was spun out of Reckitt Benckiser three years ago - generates the bulk of its revenues from Suboxone (buprenorphine and naloxone), an oral film product used for
More from news
Approximately 1 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
Impact That Matters
Using portraits and quotes from people who use drugs, the campaign urges the community to carry naloxone – a life-saving opioid overdose reversal drug.
-
Deal Watch table for May 2014
N/D. AntiOp / Reckitt Benckiser. Supply and marketing agreement. Intranasal naloxone for opioid abuse in late clinical development.
-
Pharma deals during May 2014
of alcohol abuse; and a supply and marketing agreement with AntiOp for intranasal naloxone for opioid abuse.
-
Pharma deals during November 2013
The licence is for tamper resistant oxycodone (marketed in the US since 2010) and an oxycodone/naloxone combination marketed in Europe since 2009.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide
The campaign shares their unique reasons for carrying naloxone, a drug that they now all carry. ... with a message that’s unforgettable: Carry naloxone. It could help save a life.
-
IOTOD: Improving Opioid Dependence Outcomes
dependence. In addition to the standalone conference, IOTOD now includes online education, such as webcasts, reports, and resources and tools such as the take-home naloxone (THN) toolkit.
More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- A new era for UK-Japanese scientific research relations
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- FDA issues innovative proposal to increase nonprescription drug access
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- My journey advancing the science in pulmonary hypertension
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
Envision Pharma Group
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
